The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), useful for treating CFTR mediated diseases such as cystic fibrosis.

The present invention is directed to novel compounds of formula I

##STR00001##

and their use as therapeutic compounds.

The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

##STR00001##

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film.

[Problem] Provided is a method for easily and stably storing crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate for a long term. [Solution] A method for storing packed crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or a pharmaceutically acceptable salt thereof, wherein one of the following storage conditions (1) to (3): (1) a storage temperature of 0 C. or more and less than 25 C.; (2) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.5 to 8.0; and (3) a storage temperature of 40 C. or more and less than 60 C. and a crystal pH of 5.0 to 6.4 is selected and the crystals of P.sup.1, P.sup.4-bis (5-uridyl) tetraphosphate or the pharmaceutically acceptable salt thereof are stored under the selected condition.

The present disclosure relates generally to a mucoadhesive nanoparticle delivery system. The nanoparticles are formed from amphiphilic macromolecules conjugated to a mucosal targeting moiety in such a manner that the surface of the nanoparticle is coated with the targeting moiety. The surface density of the targeting moiety can be tuned for adjustable targeting of the nanoparticles to a mucosal site without substantially compromising the stability of the particles. The particles were found to have high loading efficiency and sustained release properties at the mucosal site. The present disclosure also relates to polymers and macromolecules useful in the preparation of the mucoadhesive nanoparticles, as well as compositions, methods, commercial packages, kits and uses related thereto.

Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.

The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.

The present invention provides a pharmaceutical composition containing Guaifenesin. The invention pharmaceutical composition comprises a core containing Guaifenesin and a coating layer encapsulating the core containing Guaifenesin, and the coating layer comprises a plasticizer and a polymer, wherein the polymer is applied in the range of approximately 5 wt. % to 35 wt. % based on the total weight of the pharmaceutical composition. A method for controlled releasing an expectorant agent is also provided in the present invention.

A method for preparing mixture powders of platycodon grandiflorus and momordica charantia includes washing at least one year-old platycodon grandiflorus, and momordica charantia wherein the platycodon grandiflorus includes stem, root, and leaf portions thereof; cutting the washed platycodon grandiflorus and momordica charantia; hot air-drying the cut platycodon grandiflorus and momordica charantia in a dryer at a temperature exceeding a boiling point of hydrogen cyanide gas to remove hydrogen cyanide therefrom; pulverizing the cut and dried platycodon grandiflorus and momordica charantia to prepare platycodon grandiflorus powders and momordica charantia powders; and mixing the platycodon grandiflorus powders and momordica charantia powders to produce the mixture powders of platycodon grandiflorus and momordica charantia.